Ads
related to: drug that cures hep c in dogs side effects and warnings1800petmeds.com has been visited by 10K+ users in the past month
Working to be "the most powerful patient advocate in America" - Forbes
Search results
Results from the WOW.Com Content Network
[5] [6] It works against all six types of hepatitis C. [4] At twelve weeks following treatment between 81% and 100% of people have no evidence of hepatitis C. [7] It is taken once a day by mouth with food. [4] [5] The most common side effects are headache, diarrhea, and tiredness. [7] [8] In those with a history of hepatitis B, reactivation may ...
Ledipasvir is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. [1] After completing Phase III clinical trials, on February 10, 2014, Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. [2] [3] The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication ...
Prior to the availability of sofosbuvir, hepatitis C treatments involved 6 to 12 months of treatment with an interferon-based regimen. This regimen provided cure rates of 70% or less and was associated with severe side effects, including anemia, depression, severe rash, nausea, diarrhea, and fatigue.
Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. [8] It is a fixed-dose combination of ledipasvir and sofosbuvir. [8] Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotype 1. [9] Some evidence also supports use in HCV genotype 3 and 4. [9]
Adverse effects with these treatments were common, with 50–60% of those being treated experiencing flu-like symptoms and nearly a third experiencing depression or other emotional issues. [16] Treatment during the first six months of infection (the acute stage) is more effective than when hepatitis C has entered the chronic stage. [27]
Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors . [ 3 ]